Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?

Szczegóły
Abstrakt

Tytuł:: Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?
Autorzy:: Cox G; Glenfield Hospital, Department of Respiratory Medicine, Leicester, UK.
Walker RA
Muller S
Abrams KR
Steward WP
O'Byrne KJ
Źródło:: Pathology oncology research : POR [Pathol Oncol Res] 2000; Vol. 6 (2), pp. 87-92.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2021- : Lausanne, Switzerland : Frontiers Media S. A.
Original Publication: Budapest, Hungary : Science Press, c1995-
MeSH Terms:: Carcinoma, Non-Small-Cell Lung/*mortality
Lung Neoplasms/*mortality
Proto-Oncogene Proteins c-bcl-2/*metabolism
Adult ; Age Factors ; Aged ; Carcinoma, Non-Small-Cell Lung/metabolism ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Sex Factors ; Tumor Suppressor Protein p53/metabolism
References:: J Clin Oncol. 1996 May;14(5):1604-10. (PMID: 8622078)
Histopathology. 1996 Jul;29(1):45-50. (PMID: 8818693)
J Immunol. 1990 May 1;144(9):3602-10. (PMID: 2184193)
Hum Pathol. 1997 Sep;28(9):1079-82. (PMID: 9308733)
Cell. 1992 Apr 3;69(1):119-28. (PMID: 1555236)
Adv Immunol. 1998;70:245-79. (PMID: 9755339)
Hum Pathol. 1998 Jan;29(1):60-4. (PMID: 9445135)
Liver. 1999 Feb;19(1):25-31. (PMID: 9928762)
Cell Growth Differ. 1993 Jan;4(1):41-7. (PMID: 8424905)
Cancer Res. 1992 Oct 1;52(19):5407-11. (PMID: 1394146)
N Engl J Med. 1993 Sep 2;329(10):690-4. (PMID: 8393963)
J Clin Oncol. 1997 Jun;15(6):2456-66. (PMID: 9196162)
Cancer. 1995 Dec 1;76(11):2297-303. (PMID: 8635035)
Eur J Cancer. 1998 Apr;34(5):718-23. (PMID: 9713280)
Am J Clin Pathol. 1982 Feb;77(2):123-36. (PMID: 7064914)
Clin Cancer Res. 1996 May;2(5):915-20. (PMID: 9816250)
Chest. 1997 Jun;111(6):1710-7. (PMID: 9187198)
Mol Cell Biol. 1996 Jul;16(7):3884-92. (PMID: 8668206)
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5878-82. (PMID: 8016082)
Br J Cancer. 1995 Jul;72(1):164-9. (PMID: 7599047)
Mol Carcinog. 1997 Oct;20(2):231-9. (PMID: 9364213)
Int J Cancer. 1997 Dec 19;74(6):565-70. (PMID: 9421349)
Substance Nomenclature:: 0 (Proto-Oncogene Proteins c-bcl-2)
0 (Tumor Suppressor Protein p53)
Entry Date(s):: Date Created: 20000811 Date Completed: 20000921 Latest Revision: 20191104
Update Code:: 20240104
DOI:: 10.1007/BF03032355
PMID:: 10938137
: Czasopismo naukowe

Bcl-2 is an oncogenic protein that plays a central role in apoptosis. The association of Bcl-2 expression and prognosis in non-small cell lung cancer (NSCLC) is unclear, with some studies showing improved outcome whilst others show no survival advantage. We evaluated 178 surgically resected NSCLC specimens for Bcl-2 and p53 immunoexpression. Bcl-2 staining was present in 34.9% of cases (weakly staining 24.2%, strongly staining 10.7%), nuclear p53 in 43. 3% and cytoplasmic p53 in 10.7%. There was no association between p53 and survival. Bcl-2 immunoexpression correlated with improved outcome (p=0.04). A sub-group of strongly Bcl-2 staining cases had a poor survival compared to those that stained weakly (p=0.01). The strongly staining cases had a similar survival to negative cases. Immunointensity may therefore account for the disparity in results regarding the prognostic significance of Bcl-2 demonstrated in previous studies.

Informacja